Guardant Health (GH)
Health Care · life sciences tools & diagnostics · NASDAQ
Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
What Guardant Health does
Guardant Health is a precision oncology company that develops and provides blood-based and tissue-based genomic testing to help manage cancer patients throughout all stages of the disease. The company offers a portfolio of liquid biopsy products that provide comprehensive genomic profiling and cancer screening, enabling clinicians to make more informed treatment decisions.
Themes: precision oncology, liquid biopsy, genomics, cancer screening, NGS-based diagnostics
Fundamentals
- Price$162.59 as of 2026-10-20 close
- Market cap$21.8B as of 2026-07-24 (share count; price 2026-10-20)
- 1-year return+131.6% 2025-10-20 close $70.20 → 2026-10-20 close $162.59
- P/En/a negative earnings
- Net margin-42.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its stockholders' equity is zero or negative, where the ratio means nothing.
- Revenue growth (YoY)+32.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+29.8% SEC XBRL
- Beta1.23 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How GH compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: no valuation data.
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $335M | -$129M | -$120M | -$0.90 | -$58M† | $12M† |
| Q1 FY2026 2026-03-31 | $302M | -$121M | -$112M | -$0.85 | -$66M | $6M |
| Q4 FY2025 2025-12-31 | $281M† | -$121M† | -$128M† | -$1.00† | -$26M† | $28M† |
| Q3 FY2025 2025-09-30 | $265M | -$99M | -$93M | -$0.74 | -$35M† | $10M† |
| Q2 FY2025 2025-06-30 | $232M | -$106M | -$100M | -$0.80 | -$60M† | $6M† |
| Q1 FY2025 2025-03-31 | $203M | -$111M | -$95M | -$0.77 | -$63M | $4M |
| Q4 FY2024 2024-12-31 | $202M† | -$126M† | -$111M† | -$0.90† | -$65M† | $19M† |
| Q3 FY2024 2024-09-30 | $191M | -$117M | -$108M | -$0.88 | -$51M† | $4M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$1.1B
- Short-term investments$0
- Total debt$1.5B borrowings only; leases excluded
- Net debt$449M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Guardant Health looks technically
Guardant Health (GH) is trading 27.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 472 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 27.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $167.78 | $167.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $127.40 | $127.40 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 472 trading days ago — a "golden cross", a bullish long-term signal | 472 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($155.07 to $191.05) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 20.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $191.05 | $191.05 |
|---|---|---|
| From the 52-week high | it is 14.9% below its 52-week high (its highest price of the past year) | -14.9% |
| Above the 52-week low | it is 158.1% above its 52-week low (its lowest price of the past year) | +158.1% |
| Below the 52-week high | it is 14.9% below its highest point of the past year | 14.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $191.05 (set on 2026-10-06) | $191.05 |
| Given back of the 52-week move | over the past year its closes ranged ($64.19 to $187.22), and it has given back roughly a quarter of its rise from last year’s low — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $107.25 to $111.19. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 20.0% |
| From the all-time high | it is 14.9% below its all-time high | -14.9% |
| Nearest price level | it is trading 5.4% above a support level at $153.88 — a price it turned at three times since 2026-07-09, most recently on 2026-09-04. Since 2024-10-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.4% |
| All-time low | its lowest closing price on record is $15.81 (set on 2024-04-19) | $15.81 |
| Above the all-time low | it is 928.4% above its all-time low | +928.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 49th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.41 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.41 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $154.68 and $186.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $154.68 – $170.40 – $186.13 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges above its 200-day average price (27.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.73× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.7% since the prior reading | +0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.1% |
|---|---|---|
| Open gap | it gapped 6.7% above the previous close 56 sessions ago and has not traded back through the level it left behind at 152.35 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.7% |
| Gap filled | a 2.5% gap down opened on 2026-10-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.3 percentage points (the stock lost 9.4% while the market gained 1.0%) | -10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.2 percentage points (the stock gained 9.8% while the market gained 3.6%) | +6.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 70.0 percentage points (the stock gained 78.5% while the market gained 8.5%) | +70.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 117.0 percentage points (the stock gained 131.6% while the market gained 14.6%) | +117.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.4% of the share price. | +0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 26% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $129.03 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +26.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $166.84 — a volume-weighted average of daily closes over 58 sessions, not a true tick-by-tick VWAP. | -2.5% |
Price levels it has turned at before
GH last closed at $162.59 on 2026-10-20. Since 2024-10-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $153.88 | Support | 5.4% below the last close | turned there three times · 2026-07-09 to 2026-09-04 |
| $173.06 | Resistance | 6.4% above the last close | turned there three times · 2026-07-06 to 2026-08-26 |
| $134.49 | Support | 17.3% below the last close | turned there twice · 2026-05-29 to 2026-06-15 |
| $113.11 | Support | 30.4% below the last close | turned there twice · 2025-11-25 to 2026-02-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.31 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$201.64 range $105.00 – $240.00; median $200.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GH
- Consensus EPS estimate-$0.3166 next reporting period, as of 2026-10-16
- Estimate change, 30 days-$0.00933 from -$0.3073, on 2026-09-11, 35-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Continued operating losses and need for additional capital to fund operations.","Intense competition and potential for rapid technological obsolescence.","Regulatory risks associated with the development, approval, and commercialization of diagnostic products."]
What changed in the latest 10-Q
AI-assisted comparison of GH's 10-Q filed 2026-07-30 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (filed 2026-07-30), the Overview section added a sentence stating that in the second quarter of 2026, the company received FDA approval of its Guardant360 Liquid CDx test, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights.
- In the newer filing (filed 2026-07-30), the Overview section added that the Shield blood test is included in the American Cancer Society colorectal cancer screening guidelines, in addition to the National Comprehensive Cancer Network guidelines.
- In the newer filing (filed 2026-07-30), the revenue discussion added total revenue and net loss figures for the three and six months ended June 30, 2026 and 2025: total revenue of $335.0 million and $232.1 million for the three months, $636.6 million and $435.6 million for the six months, and net losses of $120.1 million and $99.9 million for the three months, $232.2 million and $195.1 million for the six months.
- Removed:
- The older filing (filed 2026-05-07) stated total revenue of $301.7 million and $203.5 million and net losses of $112.1 million and $95.2 million for the three months ended March 31, 2026 and 2025; these figures are not present in the newer filing.
- The older filing (filed 2026-05-07) stated cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of March 31, 2026; the newer filing stated cash, cash equivalents, and restricted cash of approximately $1.2 billion as of June 30, 2026, without mentioning marketable securities.
- Reworded:
- The newer filing (filed 2026-07-30) changed the cash position disclosure from 'cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion' as of March 31, 2026 (older filing, filed 2026-05-07) to 'cash, cash equivalents, and restricted cash of approximately $1.2 billion' as of June 30, 2026.
- The newer filing (filed 2026-07-30) changed the reference date for the Shield blood test's inclusion in screening guidelines from the National Comprehensive Cancer Network only (older filing, filed 2026-05-07) to both the National Comprehensive Cancer Network and American Cancer Society colorectal cancer screening guidelines.
- Notes:
- The provided text for the newer filing is truncated mid-sentence in the 'Factors affecting our performance' section, which may limit detection of further changes in that section.
- No materiality or legal conclusions are drawn from these changes.
Risk Factors
- Added:
- In the 2026-07-30 filing, the Insider trading arrangements disclosure identifies Alex M. Azar II, Director, as having adopted a trading arrangement on 5/21/2026 with duration 8/19/2026 - 9/15/2027, classified as Rule 10b5-1 (Y), with an indeterminable aggregate number of securities.
- In the 2026-07-30 filing, a footnote (2) was added explaining that the 10b5-1 trading plan for Alex M. Azar II provides for the sale of 50% of an indeterminable number of shares underlying certain restricted stock unit awards vesting during the arrangement.
- In the 2026-07-30 filing, exhibit 10.1 is annotated with '#' indicating a management contract or compensatory plan and includes a prior filing reference (Form 10-Q, File No. 001-38683, Exhibit 10.1, filed 5/7/2026).
- In the 2026-07-30 filing, exhibit 10.2 is titled 'Eligible Director Compensation Program, effective as of June 17, 2026' and includes prior filing reference (Form 10-Q, File No. 001-38683, Exhibit 10.2, filed 5/7/2026).
- Removed:
- In the 2026-05-07 filing, the Insider trading arrangements disclosure identifies Meghan Joyce, Director, as having adopted a trading arrangement on 3/4/2026 with duration 6/2/2026 - 6/1/2027, classified as Rule 10b5-1 (Y), with an aggregate of 28,944 securities.
- In the 2026-05-07 filing, exhibit 10.2 is titled 'Non-Employee Director Compensation Program, effective as of June 17, 2026' with 'Filed herewith' indication and no prior filing reference.
- Reworded:
- The newer filing (2026-07-30) states 'During the second quarter of fiscal 2026, there were no material changes to our previously disclosed risk factors,' while the older filing (2026-05-07) states 'During the first quarter of fiscal 2026, there were no material changes to our previously disclosed risk factors.'
- The newer filing (2026-07-30) refers to 'the fiscal quarter ended June 30, 2026' in the Insider trading arrangements section, whereas the older filing (2026-05-07) refers to 'the fiscal quarter ended March 31, 2026.'
- In the newer filing (2026-07-30), exhibit 10.1 includes a prior filing reference (Form 10-Q, File No. 001-38683, Exhibit 10.1, filed 5/7/2026) instead of the 'Filed herewith' indication used in the older filing.
- Notes:
- The provided newer source text includes materials beyond the Risk Factors section (Items 2-6, exhibits, and signatures). The comparison reflects all content in the provided excerpts, not only Item 1A.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 27 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 2 sells ($30274) — 2 selling insiders
- Last 90 days · read to 2026-10-160 buys · 27 sells ($31M) — 10 selling insiders
- Last 180 days · read to 2026-10-161 buy ($78456) · 78 sells ($123M) — 1 buying, 15 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-16. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for GH from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding GH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 19,130,039
- Reported value $2,870,101,760
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GH had 11,915,002 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
GH had 8.88% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.2 days to cover at the same settlement.
- Reported short interest (shares) 11,915,002
- Short interest (% of shares outstanding) 8.88%
- Prior settlement (shares) 11,018,331
- Reported change 8.14%
- Days to cover (reported) 6.2
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Illumina (ILMN)
- Roche (RHHBY)
- Thermo Fisher Scientific (TMO)
- Natera (NTRA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GH vs…
Guardant Health is found in…
Frequently asked questions
What does Guardant Health (GH) do?
Guardant Health is a precision oncology company that develops and provides blood-based and tissue-based genomic testing to help manage cancer patients throughout all stages of the disease. The company offers a portfolio of liquid biopsy products that provide comprehensive genomic profiling and cancer screening, enabling clinicians to make more informed treatment decisions.
What sector is Guardant Health (GH) in?
Guardant Health (GH) is classified in the Health Care sector. Its industry is life sciences tools & diagnostics. It trades on NASDAQ.
Who are Guardant Health's (GH) competitors?
Notable peers of Guardant Health (GH) include Exact Sciences, Illumina, Roche, Thermo Fisher Scientific and Natera. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in GH?
Yes — we hold 1 matched STOCK Act disclosure for GH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Guardant Health (GH) overbought or oversold right now?
Guardant Health (GH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.